ArticleChina CDC weekly2025
Confronting the Antimicrobial Resistance Crisis in China: Emerging Superbugs, Genomic Surveillance, and Innovative Countermeasures.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative genomic and resistance characterization of ST2 and ST164 carbapenem-resistantMicrobial genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antimicrobial resistance (AMR) crisis in China has escalated into a critical public health threat. Extensive antibiotic use in both clinical and agricultural settings has created strong selective pressures, promoting the emergence of resistant strains and accelerating their dissemination. This increasing threat is exemplified by the rapid spread of multidrug-resistant bacteria. Consequently, genomic surveillance of these pathogens and the development of effective countermeasures are urgently needed. In this paper, we highlight three critical dimensions of the AMR challenge in China, which include the recent emergence of resistant bacteria, genomic surveillance efforts, and progress in the development of novel antimicrobial agents. By synthesizing recent research on the evolutionary dynamics of drug-resistant pathogens in China and outlining innovative antimicrobial strategies, this study provides insights to guide evidence-based antimicrobial stewardship programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.